Factors Influencing a Specific Pathologic Diagnosis of Non-Small-Cell Lung Carcinoma

被引:6
作者
Sulpher, Jeffrey A. [1 ]
Owen, Scott P. [2 ]
Hon, Henrique [2 ]
Tobros, Kimberly [2 ]
Shepherd, Frances A. [2 ]
Sabri, Elham [3 ]
Gomes, Marcio [4 ]
Sekhon, Harman [4 ]
Liu, Geoffrey [2 ]
Canil, Christina M. [1 ]
Wheatley-Price, Paul [1 ]
机构
[1] Univ Ottawa, Dept Med, Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Div Med Oncol & Hematol,Dept Med, Toronto, ON M5S 1A1, Canada
[3] Univ Ottawa, Res Inst, Ottawa Hosp, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Pathol & Lab Med, Ottawa Hosp, Ottawa, ON, Canada
关键词
Chart review; Diagnosis; Histology; Non-small-cell lung cancer; CANCER; CHEMOTHERAPY; MUTATIONS; GEFITINIB; CYTOLOGY; EGFR; ADENOCARCINOMA; CLASSIFICATION; CARBOPLATIN; PACLITAXEL;
D O I
10.1016/j.cllc.2012.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pathologic subtyping of non-small-cell lung carcinoma is increasingly important when selecting therapy. The records of 739 patients were reviewed to identify factors associated with attaining a specific pathologic diagnosis. Only 456 (62%) of patients received a specific pathologic diagnosis, which was significantly associated with histologic biopsy samples, immunohistochemical testing, and diagnosis outside of an academic center. Introduction: Historically, a non-small-cell lung carcinoma diagnosis, without pathologic subclassification, provided sufficient information to guide therapy. Evidence now demonstrates that pathologic subtype classification is central in selecting optimal treatment. This review aimed to identify factors associated with a specific pathologic diagnosis. Methods: All nonoperative cases of non-small-cell lung carcinoma (NSCLC) referred to the medical oncology divisions of the Ottawa Hospital Cancer Centre (2008) and Princess Margaret Hospital, Toronto (2007-2010) were identified. The charts were reviewed for demographics, diagnostic methods, and final diagnosis. Logistic regression was performed to identify variables associated with a specific diagnosis. Results: Of 739 patient records analyzed, 377 (51%) were men, 299 (40%) were aged over 70 years, and 510 (69%) had an Eastern Cooperative Oncology Group performance status of 0-2. Three hundred and eighty five (52%) of patients were diagnosed in a tertiary academic center. The lung primary was sampled in 503 (68%) of patients. Computed tomography-guided biopsy (n = 370, 50%) and bronchoscopy (n = 179, 24%) were the most common techniques. Four hundred and seventy seven (65%) of biopsies were cytologic specimens alone, and immunohistochemistry was performed in 337 (46%) of cases. The most common diagnoses were adenocarcinoma (n = 338, 46%), NSCLC not otherwise specified (n = 254, 34%), and squamous cell carcinoma (n = 115, 16%). Overall, 456 (62%) of patients received a specific pathologic diagnosis. Factors significantly associated with attaining a specific pathologic diagnosis were diagnosis outside an academic center (adjusted odds ratios [OR] 2.1 [95% CI, 1.41-3.14]; P = .0003), histologic laboratory samples (adjusted OR 1.58 [95% CI, 1.003-2.49]; P = .049), and immunohistochemical testing (adjusted OR 1.82 [95% CI, 1.25-2.70], P = .0021). Conclusions: A significant minority of patients with NSCLC do not receive a specific pathologic diagnosis. In an era of individualized medicine, this may potentially impact optimal clinical management. Clinical Lung Cancer, Vol. 14, No. 3, 238-44 (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 50 条
[41]   Problems involved in the clinical trials for non-small cell lung carcinoma [J].
Saijo, Nagahiro .
CANCER TREATMENT REVIEWS, 2012, 38 (03) :194-202
[42]   A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non-Small-Cell Lung Cancer [J].
Pallis, Athanasios G. ;
Voutsina, Alexandra ;
Kentepozidis, Nikolaos ;
Giassas, Stylianos ;
Papakotoulas, Pavlos ;
Agelaki, Sofia ;
Tryfonidis, Kostas ;
Kotsakis, Athanasios ;
Vamvakas, Lambros ;
Vardakis, Nikolaos ;
Georgoulias, Vassilis .
CLINICAL LUNG CANCER, 2012, 13 (02) :129-135
[43]   Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation [J].
Kim, Young Hak ;
Nishimura, Takashi ;
Ozasa, Hiroaki ;
Nagai, Hiroki ;
Sakamori, Yuichi ;
Iwata, Toshiyuki ;
Sunadome, Hironobu ;
Nishimura, Tomoko ;
Mishima, Michiaki .
CHEMOTHERAPY, 2013, 59 (06) :414-419
[44]   Analysis of the effect of NEKs on the prognosis of patients with non-small-cell lung carcinoma based on bioinformatics [J].
Yang, Mengxia ;
Guo, Yikun ;
Guo, Xiaofei ;
Mao, Yun ;
Zhu, Shijie ;
Wang, Ningjun ;
Lu, Dianrong .
SCIENTIFIC REPORTS, 2022, 12 (01)
[45]   Coexistence of non-Hodgkin's lymphoma and non-small-cell lung carcinoma: Diagnosis and treatment [J].
Rothenburger, M ;
Semik, M ;
Hoffmeier, A ;
Baba, H ;
Kamanbrou, D ;
Roos, N ;
Schmidt, C ;
Scheld, HH .
THORACIC AND CARDIOVASCULAR SURGEON, 2002, 50 (01) :59-61
[46]   EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry [J].
Mraihi, Zohra ;
Ben Amar, Jihen ;
Bouacha, Hend ;
Rammeh, Soumaya ;
Hila, Lamia .
BMC PULMONARY MEDICINE, 2018, 18
[47]   Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology [J].
Mithoowani, Hamid ;
Febbraro, Michela .
CURRENT ONCOLOGY, 2022, 29 (03) :1828-1839
[48]   Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application [J].
Sun, Hao ;
Wu, Yi-Long .
FUTURE ONCOLOGY, 2019, 15 (23) :2769-2777
[49]   Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients [J].
Garrana, Sherief H. ;
Dagogo-Jack, Ibiayi ;
Cobb, Rosemary ;
Kuo, Anderson H. ;
Mendoza, Dexter P. ;
Zhang, Eric W. ;
Heeger, Allen ;
Sequist, Lecia, V ;
Digumarthy, Subba R. .
CLINICAL LUNG CANCER, 2021, 22 (01) :23-31
[50]   Brain metastases from non-small-cell lung cancer: is there room for improvement? [J].
Franceschi, Enrico ;
Brandes, Alba A. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (04) :421-423